It's almost as if you don't know how Akida, as a product will be sold to market, or you are being deliberately misleading.BRN doesn't plan to manufacture anything, nor does it have the reach to engage every possible customer. Better to partner with those who have the connections to industry and reward them for facilitating the inking of IP agreements, rather than employing a massive sales team in house. - mjshackl
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
CORRECT 100% mjshackl
BRN have stated they have changed mode to being ONLY an IP provider & Chips for Customer evaluation only.
98% profit on IP revenue from previous BRN statement also.
----------------------------------------------------------------------------------
"BrainChip – Annual General Meeting CEO and Chairman’s Address Sydney 24 May 2022: BrainChip Holdings Ltd (ASX:BRN), appends the Chairman’s address, Chief Executive Officer’s address and presentation to the Annual General Meeting, in accordance with the ASX Listing Rules.
This announcement is authorised for release by the BRN Board of Directors."
CEO Sean Hehir statement regarding his due diligence process regarding his appointment -
"Being a Silicon Valley based executive I had easy access to some of the world’s best technical minds who I engaged to evaluate the core technology.
The overwhelming feedback was the technology is visionary in its design, unparalleled in flexibility, and transformative in performance.
The Market is moving to the edge, and we are already here...
..........................
Ok above says it all................
Yak52
- Forums
- ASX - By Stock
- BrainChip inks new partnerships in Europe, Israel to expand EMEA sales
It's almost as if you don't know how Akida, as a product will be...
Featured News
Add BRN (ASX) to my watchlist
(20min delay)
|
|||||
Last
27.0¢ |
Change
0.025(10.2%) |
Mkt cap ! $501.1M |
Open | High | Low | Value | Volume |
25.0¢ | 29.5¢ | 24.5¢ | $7.291M | 27.26M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 274904 | 27.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
27.5¢ | 118900 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 274904 | 0.270 |
10 | 641171 | 0.265 |
17 | 657403 | 0.260 |
9 | 292867 | 0.255 |
32 | 648414 | 0.250 |
Price($) | Vol. | No. |
---|---|---|
0.275 | 118900 | 4 |
0.280 | 3087044 | 3 |
0.285 | 200000 | 1 |
0.290 | 188281 | 5 |
0.295 | 777218 | 21 |
Last trade - 16.10pm 06/05/2024 (20 minute delay) ? |
|
|||||
Last
27.3¢ |
  |
Change
0.025 ( 11.0 %) |
|||
Open | High | Low | Volume | ||
25.0¢ | 29.5¢ | 24.5¢ | 19285151 | ||
Last updated 15.59pm 06/05/2024 ? |
Featured News
BRN (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, CEO
Steven Gourlay
CEO
Previous Video
Next Video
SPONSORED BY The Market Online